New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
08:02 EDTMYLMylan launches first generic Klor-Con Extended-release tablets
Mylan announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq and 10 mEq, which is the generic version of Upsher-Smith's Klor-Con. Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product. Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7B in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25B in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
10:14 EDTMYLMylan November calls active on takeover speculation
Mylan November 55 & 57.5 calls are active on total call volume of 7,100 contracts (200 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 32 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:51 EDTMYLRumor: Mylan strength attributed to takeover speculation
Subscribe for More Information
November 13, 2014
07:38 EDTMYLBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use